Get the Stockscreener App
7.1498
6.17%
-0.4702
Adaptive Biotechnologies Corp stock is traded at $7.1498, with a volume of 396.62K.
It is down -6.17% in the last 24 hours and down -16.08% over the past month.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
See More
Previous Close:
$7.62
Open:
$7.5
24h Volume:
396.62K
Relative Volume:
0.27
Market Cap:
$1.06B
Revenue:
$177.28M
Net Income/Loss:
$-195.24M
P/E Ratio:
-5.3357
EPS:
-1.34
Net Cash Flow:
$-114.54M
1W Performance:
-7.98%
1M Performance:
-16.08%
6M Performance:
+55.10%
1Y Performance:
+109.68%
1-Day Range:
$6.96
$7.57
1-Week Range:
$6.255
$7.92
52-Week Range:
$2.28
$8.95
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Name
Adaptive Biotechnologies Corp
Sector
Industry
Phone
206-659-0067
Address
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
7.15 | 1.06B | 177.28M | -195.24M | -114.54M | -1.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.03 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
679.80 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
579.20 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.18 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.04 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Dec-21-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Underperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Reiterated | BTIG Research | Buy |
| Feb-16-22 | Reiterated | BofA Securities | Buy |
| Feb-16-22 | Reiterated | Goldman | Neutral |
| Feb-16-22 | Reiterated | JP Morgan | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Mar-03-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-03-20 | Initiated | Goldman | Buy |
| Jul-23-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | BofA/Merrill | Buy |
| Jul-22-19 | Initiated | Cowen | Outperform |
| Jul-22-19 | Initiated | Goldman | Neutral |
| Jul-22-19 | Initiated | Guggenheim | Buy |
| Jul-22-19 | Initiated | William Blair | Outperform |
View All
Adaptive Biotechnologies Corp Stock (ADPT) Latest News
Adaptive Biotechnologies director sells shares worth $70,500 By Investing.com - Investing.com Canada
Adaptive Biotechnologies director sells shares worth $402,270 - Investing.com
Adaptive Biotechnologies director sells shares worth $70,500 - Investing.com
Adaptive Biotechnologies director sells shares worth $402,270 By Investing.com - Investing.com UK
Adaptive Biotechnologies Executives Sell Shares - TradingView
US Bancorp DE Sells 43,819 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Insider Selling: Adaptive Biotechnologies Co. (NASDAQ:ADPT) CEO Sells $819,109.98 in Stock - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.5% on Insider Selling - Defense World
Adaptive Biotechnologies CEO Chad Robins sells $1.6 million in stock By Investing.com - Investing.com Australia
Adaptive Biotechnologies’ chief commercial officer Sharon Benzeno sells $311,792 in stock By Investing.com - Investing.com South Africa
Principal Financial Group Inc. Purchases Shares of 143,444 Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies president Julie Rubinstein sells $415,539 in stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies CFO sells shares worth $72,072 By Investing.com - Investing.com South Africa
Adaptive Biotechnologies’ chief scientific officer sells $675k in stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies chief people officer sells $145,845 in stock - Investing.com
Adaptive Biotechnologies director sells $124,372 in stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies director sells $124,372 in stock - Investing.com India
Adaptive Biotechnologies president Julie Rubinstein sells $415,539 in stock - Investing.com India
Adaptive Biotechnologies CEO Chad Robins sells $1.6 million in stock - Investing.com
Adaptive Biotechnologies CFO sells shares worth $72,072 - Investing.com
Private Advisor Group LLC Makes New $264,000 Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Holdings Increased by Rhumbline Advisers - Defense World
D.A. Davidson & CO. Buys 6,725 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies’ (ADPT) “Overweight” Rating Reiterated at Piper Sandler - Defense World
Cathie Wood’s Ark Invest Makes Bold Moves: Buys BEAM & NU, Sells MELI & ADPT - Apna Kal
Cathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive BiotechnologiesARK Fintech Innovation ETF (ARCA:ARKF), Adaptive Biotechnologies (NASDAQ:ADPT) - Benzinga
Adaptive Biotechnologies CEO Chad Robins sells over $2.4m in stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies CEO Chad Robins sells over $2.4m in stock - Investing.com Canada
Cathie Wood’s ARK buys Beam Therapeutics, sells Adaptive Biotech stock - Investing.com India
Cathie Wood's ARK buys Beam Therapeutics, sells Adaptive Biotech stock By Investing.com - Investing.com Australia
Cathie Wood's ARK buys Beam Therapeutics, sells Adaptive Biotech stock - Investing.com
Adaptive Biotechnologies CEO Chad Robins sells $3.99 million in shares By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies CEO Chad Robins sells $3.99 million in shares - Investing.com India
Adaptive Biotechnologies CEO Chad M Robins Sells Over $3.9 Million in Company Stock - TradingView
ADPT stock soars to 52-week high, reaching $8.33 - MSN
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Up 7.9% Following Analyst Upgrade - Armenian Reporter
Scotiabank Forecasts Strong Price Appreciation for Adaptive Biotechnologies (NASDAQ:ADPT) Stock - Defense World
Legato Capital Management LLC Decreases Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Up 7.9% on Analyst Upgrade - MarketBeat
Scotiabank Issues Positive Forecast for Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price - MarketBeat
Adaptive Biotechnologies price target raised to $12 from $10 at Scotiabank - Yahoo Finance
Adaptive Biotechnologies targets $1,300 ASP for MRD tests in 2025 driven by pricing improvements - MSN
Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue Estimates - MSN
Adaptive Biotechnologies (NASDAQ:ADPT) Reaches New 1-Year High After Analyst Upgrade - MarketBeat
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Down 5.2%Time to Sell? - MarketBeat
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2024 Earnings Call Transcript - Insider Monkey
ADPT stock soars to 52-week high, reaching $8.33 By Investing.com - Investing.com South Africa
Adaptive Biotechnologies Corp (ADPT) Q4 2024 Earnings Call Highlights: Strong MRD Revenue ... By GuruFocus - Investing.com Canada
Adaptive Biotechnologies Corp (ADPT) Q4 2024 Earnings Call Highl - GuruFocus.com
Adaptive Biotechnologies: Q4 Earnings Snapshot - The Advocate
Adaptive Biotechnologies Corp (ADPT) Q4 2024 Earnings Call Highlights: Strong MRD Revenue ... - Yahoo Finance
Adaptive Biotechnologies Corp Stock (ADPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):